Get started
Author

Cristina Fernandez‐Ibarra

First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
2013 · Cristiana Sessa, Geoffrey I. Shapiro, et al. · Clinical Cancer Research · 161
89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients
2014 · Sietske B.M. Gaykema, Carolien P. Schröder, et al. · Clinical Cancer Research · 121
Phase 1/1 B trial of the heat shock protein 90 inhibitor NVP ‐ AUY 922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma
2015 · Ruth Seggewiss‐Bernhardt, Ralf C. Bargou, et al. · Cancer · 73
PDF
Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an HSP90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer.
2011 · C. P. Schroder, J. V. Pedersen, et al. · Journal of Clinical Oncology · 25
Data from 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients
2023 · Sietske B.M. Gaykema, Carolien P. Schröder, et al.
Supplementary Figure 1, Tables 1 - 4 from 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients
2023 · Sietske B.M. Gaykema, Carolien P. Schröder, et al.
Data from 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients
2023 · Sietske B.M. Gaykema, Carolien P. Schröder, et al.
Supplementary Figure 1, Tables 1 - 4 from 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients
2023 · Sietske B.M. Gaykema, Carolien P. Schröder, et al.
Supplemenary Material from First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
2023 · Cristiana Sessa, Geoffrey I. Shapiro, et al.
Supplemenary Material from First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
2023 · Cristiana Sessa, Geoffrey I. Shapiro, et al.
Data from First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
2023 · Cristiana Sessa, Geoffrey I. Shapiro, et al.
Data from First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
2023 · Cristiana Sessa, Geoffrey I. Shapiro, et al.
Works count: 12
Citation count: 380
H-index: 4
I10-index: 4
Year
Topic
Type